Advertisement

Topics

Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain

14:33 EDT 3 Aug 2017 | SCRIP

US advisory committee recommends approval of new indication for the JAK inhibitor but does not want any radiographic progression data...

      

Related Stories

 

Original Article: Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain

NEXT ARTICLE

More From BioPortfolio on "Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain"

Quick Search
Advertisement